Clinical Trial Update: Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating Bevespi's effects on ventilation and gas exchange abnormalities in COPD using 129Xe MRI; study completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Bevespi (glycopyrronium and formoterol fumarate single inhaler combination)

Snippet

Sponsor: Bastiaan Driehuys | Conditions: COPD | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-01-19